[go: up one dir, main page]

UA99308C2 - Аналог азацитидина и его применение - Google Patents

Аналог азацитидина и его применение

Info

Publication number
UA99308C2
UA99308C2 UAA201004927A UAA201004927A UA99308C2 UA 99308 C2 UA99308 C2 UA 99308C2 UA A201004927 A UAA201004927 A UA A201004927A UA A201004927 A UAA201004927 A UA A201004927A UA 99308 C2 UA99308 C2 UA 99308C2
Authority
UA
Ukraine
Prior art keywords
integer
formula
rchoc
rchnhc
ris
Prior art date
Application number
UAA201004927A
Other languages
English (en)
Ukrainian (uk)
Inventor
Льюис СИЛВЕРМАН
Джеймс Холланд
Марит Лиланд САНДВОЛЬД
Финн МЮРЕН
Оле Хенрик ЭРИКСЕН
Original Assignee
Маунт Синай Скул Оф Медсин
Клавис Фарма Аса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маунт Синай Скул Оф Медсин, Клавис Фарма Аса filed Critical Маунт Синай Скул Оф Медсин
Publication of UA99308C2 publication Critical patent/UA99308C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Данное изобретение относится к соединениям формулы (I), которая приведена ниже, где R представляет собой Н, RC(O), RCHOC(O) или RCHNHC(O), Rпредставляет собой фрагмент, соответствующий формулам, приведенным ниже, где перекрещивающаяся пунктирная линия, показывает связь, образованную присоединением Rк молекуле формулы (I); Rи Rнезависимо представляет собой ОН или Н, при условии, что Rи Rодновременно не является ОН; Rпредставляет собой Н, RC(O), RCHOC(O) или RCHNHC(O), при условии, что R и Rодновременно не является Н, Rсоответствует общей формуле: CH(CH)(CH=CH-CH)-CH=CH-(CH); k представляет собой целое число от 0 до 7; m представляет собой целое число от 0 до 2; и n представляет собой целое число от 0 до 10; или их фармацевтически приемлемые соли. Раскрыты также способы получения и применения указанных соединений.
UAA201004927A 2007-09-26 2008-09-25 Аналог азацитидина и его применение UA99308C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26

Publications (1)

Publication Number Publication Date
UA99308C2 true UA99308C2 (ru) 2012-08-10

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201004927A UA99308C2 (ru) 2007-09-26 2008-09-25 Аналог азацитидина и его применение
UAA201004928A UA99836C2 (en) 2007-09-26 2008-09-25 Azacytidine analogue and using thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201004928A UA99836C2 (en) 2007-09-26 2008-09-25 Azacytidine analogue and using thereof

Country Status (15)

Country Link
US (2) US8399420B2 (ru)
EP (2) EP2197274A4 (ru)
JP (2) JP2010540555A (ru)
KR (2) KR20100072230A (ru)
CN (2) CN101815437A (ru)
AU (2) AU2008304381A1 (ru)
BR (2) BRPI0817234A2 (ru)
CA (2) CA2700267A1 (ru)
IL (1) IL204690A0 (ru)
MX (2) MX2010003261A (ru)
NZ (2) NZ583824A (ru)
RU (1) RU2488591C2 (ru)
UA (2) UA99308C2 (ru)
WO (2) WO2009042767A1 (ru)
ZA (1) ZA201001660B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
US8399420B2 (en) * 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
EP3782611B1 (en) 2008-05-15 2022-07-06 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
WO2010129211A2 (en) * 2009-04-27 2010-11-11 Dr. Reddy's Laboratories Ltd. Preparation of decitabine
US9393255B2 (en) 2011-01-31 2016-07-19 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
US9125884B2 (en) 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
BR112014020786A2 (pt) 2012-02-24 2020-10-27 Signal Pharmaceuticals, Llc método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
HK1221144A1 (zh) * 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
SG11201705069YA (en) * 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
EP3383406B1 (en) 2015-12-03 2021-10-20 Epidestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
CN110446504B (zh) 2017-03-20 2024-07-26 瓦西尼斯公司 用脑信号蛋白-4d抗体联合表观遗传调节剂治疗癌症
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2019256465B2 (en) * 2018-04-19 2024-10-03 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2022035852A1 (en) * 2020-08-10 2022-02-17 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (ru) 1963-12-22
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3737456A1 (de) 1986-11-04 1988-05-19 Fuji Photo Film Co Ltd Laserlichtquelle
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
WO1992015113A1 (en) * 1991-02-19 1992-09-03 Fujitsu Limited Semiconductor device having an isolation region enriched in oxygen and a fabrication process thereof
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
JPH06510285A (ja) 1991-08-14 1994-11-17 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド 抗不整脈及び抗細動剤として有用な環状ウレタン類
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
GB9515279D0 (en) * 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
BR9610070A (pt) 1995-08-08 1999-07-27 Univ Jefferson Sequência de ácido nucleico polipetídeos compostos antifibrótico e processo para tratar distúrbios ou doenças relacionadas com fibrose para usar a sequência de dna e para produzir c-proteinase recombinante
US5760063A (en) 1995-09-15 1998-06-02 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
JPH10158192A (ja) * 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
KR100483256B1 (ko) 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
AU754370B2 (en) * 1997-06-03 2002-11-14 Itochu Techo-Chemical Inc. Natural antitumor or antiviral substances and use of the same
CA2311581A1 (en) 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
EP1078917A4 (en) 1998-02-17 2002-11-06 Ono Pharmaceutical Co AMIDINO DERIVATIVES FOR USE AS ACTIVE INGREDIENTS AND MEDICINES CONTAINING THEM
AU5073100A (en) 1999-06-09 2001-01-02 Bayer Aktiengesellschaft Pyridine carboxamides and their use as plant protection agents
WO2001018013A1 (en) 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
WO2001029011A2 (en) * 1999-10-15 2001-04-26 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
AU2002356672A1 (en) 2001-11-21 2003-06-10 Ganymed 256 Vermogensverwaltungs Gmbh Phospholipid derivitives of nucleosides as antitumoral medicaments
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
EP1545558A4 (en) 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
JPWO2004101593A1 (ja) 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2548283A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
JP2007520527A (ja) 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007035783A2 (en) 2005-09-19 2007-03-29 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
BRPI0616574A2 (pt) 2005-09-27 2009-11-24 Shionogi & Co derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) * 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
US8399420B2 (en) * 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof

Also Published As

Publication number Publication date
EP2205073A4 (en) 2013-03-06
US20090209482A1 (en) 2009-08-20
WO2009042766A9 (en) 2009-05-28
WO2009042767A1 (en) 2009-04-02
NZ583923A (en) 2012-05-25
EP2205073A1 (en) 2010-07-14
RU2488591C2 (ru) 2013-07-27
AU2008304381A1 (en) 2009-04-02
WO2009042766A1 (en) 2009-04-02
RU2010116274A (ru) 2011-11-10
US8399420B2 (en) 2013-03-19
JP2010540556A (ja) 2010-12-24
KR20100102092A (ko) 2010-09-20
MX2010003261A (es) 2010-08-18
BRPI0817234A2 (pt) 2014-09-30
US8158605B2 (en) 2012-04-17
CA2700267A1 (en) 2009-04-02
UA99836C2 (en) 2012-10-10
US20090209477A1 (en) 2009-08-20
AU2008304380A1 (en) 2009-04-02
NZ583824A (en) 2012-06-29
EP2197274A4 (en) 2013-03-06
IL204690A0 (en) 2010-11-30
CA2700207A1 (en) 2009-04-02
JP2010540555A (ja) 2010-12-24
MX2010003002A (es) 2010-07-05
ZA201001660B (en) 2011-05-25
KR20100072230A (ko) 2010-06-30
CN101815437A (zh) 2010-08-25
BRPI0817269A2 (pt) 2014-10-07
CN101877964A (zh) 2010-11-03
EP2197274A1 (en) 2010-06-23
RU2010116154A (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
UA99308C2 (ru) Аналог азацитидина и его применение
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
PT1853588E (pt) Compostos químicos
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
WO2008064018A8 (en) Thienopyrimidinones for treatment of inflammatory disorders and cancers
WO2009016410A3 (en) Chemical compounds 831
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
MY159260A (en) Pharmaceutical composition and poria extract useful for enhancing absorption of nutrients
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
WO2007117591A3 (en) Total synthesis of salinosporamide a and analogs thereof
TW200720260A (en) Prokineticin 1 receptor antagonists
MY139454A (en) 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
TW200716547A (en) Piperidin-4-yl-amide derivatives
TW200745122A (en) New compounds I
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
WO2009027736A3 (en) 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
MY141233A (en) Enantiomers of selected fused heterocyclics and uses thereof
WO2007095021A3 (en) Novel compounds
WO2004087673A3 (en) Migrastatin analogs and uses thereof
WO2007128829A3 (en) 18,21-didesoxymacbecin derivatives for the treatment of cancer